Companies › F2G
1 active drug program in 2 registered trials: 1 Phase 3, 1 Phase 2; Infectious disease.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Olorofim (F901318) Dihydroorotate dehydrogenase (quinone), mitochondrial inhibitor | FKBP12 | Phase 3 | Invasive Aspergillosis; Coccidioidal Meningitis | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05101187 | Olorofim (F901318) | Phase 3 | Invasive Aspergillosis | Infectious disease | Nov 2025 |
| NCT07385638 | Olorofim (F901318) | Phase 2 | Coccidioidal Meningitis | Infectious disease | Mar 2027 |
–
TCM Biotech International Vivacelle Bio Ansun Biopharma SymBio Pharmaceuticals Baxis Pharmaceuticals
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.